ColiFin (colistimethate sodium)

ColiFin is an inhaled formulation of colistimethate sodium, a cyclic polypeptide antibiotic belonging to the polymyxin class. It is specifically developed for the treatment of chronic pulmonary infections caused by *Pseudomonas aeruginosa*, particularly in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis (NCFB). As a prodrug, colistimethate sodium is converted into colistin, which acts as a cationic surfactant. It binds to the lipid A component of lipopolysaccharides and phospholipids in the outer membrane of Gram-negative bacteria, displacing calcium and magnesium ions. This disruption increases membrane permeability, leading to the leakage of intracellular contents and bacterial cell death. ColiFin is typically administered using high-efficiency nebulizers such as the eFlow technology developed by PARI Pharma.

Brand names

ColiFin

Other names

colistin methanesulfonatecolistin sulfomethate sodiumcolistimethate